Canakinumab
Brand:
NICE TA: 281 (terminated)
Indication: Gouty arthritis (NICE 281 - terminated appraisal)
Disease category: Musculoskeletal and joint disease
Commissioning responsibility: CCG
PbR excluded: Yes
Background
The NICE appraisal was suspended as the manufacturer had not engaged with the NICE review process.
Recommendation
LMMG recommendation: Black
Click here to find the definitions for the colour classifications
Reason for decision: Uncertaintly around the risk to benefit ratio with safety concerns around cardiovascular and renal function, serious infections and neutropenia.
Supporting documents:
Decisions of Lancashire local decision making groups:
NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
---|---|---|---|---|---|
Black |
Black |
Black |
Black |
Black |
Black |